|| mutation (3%-5% of nsclc patients) 6, 7 , the approach to treatment is moving toward targeted agents. Although many such patients will ultimately receive chemotherapy, targeted agents allow for a personalized approach to treatment through identification of the presence of gene profiles or disease-specific genes that control cancer growth.
INTRODUCTION
Non-small-cell lung cancer (nsclc), with its three main histologic subtypes, adenocarcinoma, squamous cell carcinoma, and large cell anaplastic carcinoma, accounts for approximately 85% of all lung cancers 1, 2 . The heterogeneous histologies of nsclc have traditionally been grouped because of similarities in treatment and prognosis; however, evidence shows that they can respond differently to treatment 3 .
Most patients with nsclc receive chemotherapy as first-line treatment. However, in nsclc patients with either an EGFR mutation (10%-15% of white 4 and 20%-40% of Asian 5 nsclc patients) or an ALK Current OnCOlOgy-VOlume 21, number 6, DeCember 2014 Multimed Inc. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC).
to be primarily secretory, although the mechanism remains unclear 22, 23 .
Several possible mechanisms for egfr t k iinduced diarrhea have been postulated. One theory proposes that, in normal gastrointestinal mucosa, egfr, a negative regulator of chloride secretion, is often overexpressed 23 . The egfr tkis might block that regulation pathway, increasing chloride secretion, which would induce secretory diarrhea 23, 24 . An alternative theory is that the egfr tkis inhibit egfr signalling, leading to a reduction in growth and impaired healing of the intestinal epithelium where egfr is expressed, subsequently causing mucosal atrophy 25 . It has also been suggested that a combination of factors cause egfr tki-induced diarrhea, including altered gut motility, colonic crypt damage, changes in the intestinal microflora, and altered colonic transport 21 . Finally, data from the Skin Toxicity Evaluation Protocol with Panitumumab (stepp) trial showed that patients using a prophylactic skin treatment regimen that included oral doxycycline 100 mg twice daily were less likely than patients on a reactive skin treatment regimen to experience any grade of diarrhea (56% and 85% respectively) 26 . Doxycycline could be acting as an anti-inflammatory or an antimicrobial agent, suppressing diarrhea caused by the egfr inhibitor panitumumab, suggesting that an inflammatory or infectious component might be involved.
ASSESSMENT AND GRADING
The guideline most commonly used to determine the severity of diarrhea is the Common Terminology Criteria for Adverse Events from the U.S. National Cancer Institute (Table i) 27 . The ae grades are determined in part by the increase in the number of stools per day over baseline: grade 1 is an increase of less than 4 stools, grade 2 is an increase of 4-6 stools, and grade 3 is an increase of 7 or more stools. In addition, grade 3 includes incontinence limiting selfcare activities of daily living, with hospitalization indicated. Grade 4 is considered life-threatening with urgent intervention indicated, and grade 5 is death.
However, using the Common Terminology Criteria for Adverse Events alone is not sufficient to provide a complete assessment. During evaluation of the patient, additional information should be gathered, including stool characteristics and coexisting symptoms and their duration 28 .
In addition, causes of diarrhea other than the egfr tki should be ruled out. Other potential causes of diarrhea include medications (stool softeners, antacids, laxatives, antibiotics), diet intolerances (lactose, for instance), radiation toxicity, surgeries (short bowel syndrome or gastrectomy), fecal impaction, intestinal obstruction, and comorbid infections. Laboratory tests can rule out some causes of diarrhea: neutropenia can be detected from a complete blood count and differential, renal function and electrolyte abnormalities can be assessed using blood tests, and bacterial pathogens can be checked through a stool culture or Clostridium difficile toxin screen. To rule out coexisting disorders such as bowel ischemia, perforation, or obstruction, evaluation with abdominal radiography or endoscopy and biopsy can be performed 8, 28, 29 .
INCIDENCE OF DIARRHEA
In phase iii clinical trials involving egfr tkis, the incidence of diarrhea varied substantially by drug and dosage given (Table ii) . In the trials, the incidence of diarrhea ranged from 18% to 95%, with up to 25% of patients experiencing grade 3 or higher diarrhea.
Interestingly, the incidence of grade 3 diarrhea in the lux-Lung 3 trial, which compared afatinib with chemotherapy, was 14.4% for patients who received afatinib 60 . However, in the lux-Lung 6 trial, which was completed after the lux-Lung 3 trial, the incidence of grade 3 diarrhea was 5.4% for patients who received afatinib-a substantial difference 67 . The main differences in these trials were the type of chemotherapy given (which would not affect the ae profile of patients in the afatinib arm) and the ethnic origin of the patient population. The lux-Lung 6 trial had an all-Asian population; the ethnicity of the patient population in lux-Lung 3 was 72% eastern Asian, 26% white, and 2% other. The difference in severe diarrhea had been speculated to be a result of the difference in the ethnicities of the study populations. However, a recent analysis comparing the incidence of diarrhea in the two trials by ethnicity showed comparable results between the groups (grade 3 diarrhea occurred in 9.7% of the Asian patients and in 10.9% of the non-Asian patients) 68 . The treatment protocols for diarrhea were consistent across the two trials, but the heightened awareness of the importance of treating diarrhea early might have been the reason that the incidence of high-grade events dropped in the lux-Lung 6 trial. In addition, the oncologists in the lux-Lung 3 trial were less experienced at treating egfr tki-induced diarrhea because of the small number of patients (1-3 patients) in some centres.
IMPACT OF DIARRHEA
Diarrhea can cause discomfort, fatigue, and sleep disturbance, and can affect social functioning because patients are reluctant to leave the house. Alterations in gastrointestinal transit and digestion can lead to nutritional deficiencies that can negatively affect quality of life. Severe diarrhea can result in fluid and electrolyte loss, which can lead to dehydration, electrolyte imbalances, and renal insufficiency 28 . Notably, although most clinical trial results do not report moderate diarrhea (grade 2) as a separate category (they usually report all grades and grades 3 and 4), in our expert opinion, grade 2 diarrhea is not inconsequential and can have a significant effect on quality of life. Although diarrhea can have a profound effect on patients, available evidence suggests that diarrhea is an indicator that egfr tkis are working effectively. In a retrospective study of patients with nsclc treated with gefitinib on the Expanded Access Program at the MD Anderson Cancer Center, univariate and multivariate analyses were used to determine relationships between patient characteristics and treatment outcomes. Among patients who received gefitinib 250 mg, the presence of diarrhea was identified as one of the independent predictors of a partial response, and the absence of diarrhea was one of the predictors of progressive disease 69 . A study of egfr tkis that included data from phase ii clinical trials of gefitinib and erlotinib in patients with recurrent and metastatic squamous cell carcinoma of the head and neck showed a similar association between egfr tki-induced diarrhea and clinical benefit and also an association with more favourable overall survival 70 . Finally, combined ae data from the lux-Lung 3 and lux-Lung 6 trials comparing afatinib with chemotherapy in patients with EGFR mutation-positive nsclc showed a trend toward a higher rate of progression-free survival in patients who had grade 2 or greater diarrhea in the first 28 days of treatment with afatinib (compared with patients who experienced no aes); however, no statistically significant differences were observed 65 .
MANAGEMENT
Diarrhea associated with taking an egfr tki usually ranges from mild (grade 1) to moderate (grade 2). Dietary changes and antidiarrheal medications are usually sufficient to control diarrhea 8, 28, 29, 71 . However, to avoid escalation of symptoms and to prevent dose reduction or discontinuation of the egfr tki, it is critical to manage symptoms and fluid intake early. Management of egfr tki-induced diarrhea is identical to management of chemotherapy-induced diarrhea and includes patient education and both nonpharmacologic and pharmacologic management strategies.
Education and Nonpharmacologic Management Strategies
Patient education should ideally begin before treatment and continue throughout treatment. Patients should be advised to discuss with the health care team any symptoms of diarrhea as soon as they occur. It is critical that patients understand the importance of managing symptoms early and aggressively to avoid egfr tki discontinuation, which has negative consequences. For the first 4 weeks of treatment, a nurse familiar with egfr tki-induced diarrhea should be assigned to speak with the patient every week, in person or on the telephone, to monitor aes that might occur. Patients should also be advised of nonpharmacologic management strategies, which include dietary change, fluid intake, and probiotics. A patient 8, 28, 29, 71 . In addition to dietary changes, patients should drink 3-4 L of fluid daily to prevent dehydration. To avoid hyponatremia or hypokalemia from loss of electrolytes, some of the fluid intake should include sugar or salt 21 .
There is some evidence that supplementation with probiotics might reduce the severity of chemotherapy-induced diarrhea and abdominal discomfort, with few or no aes 72 . In a study by Österlund et al., Lactobacillus supplementation reduced the frequency of grades 3 and 4 diarrhea 73 . Compared with patients in the control arm of the study, patients who received supplementation with Lactobacillus during chemotherapy also reported less abdominal discomfort and had fewer chemotherapy dose reductions 73 , findings that might potentially apply to egfr tki-induced diarrhea. However, no clinical trials have specifically evaluated the role of probiotics in diarrhea caused by egfr tkis.
Pharmacologic Management Strategies
Pharmacologic management of egfr tki-induced diarrhea is based on the grade of diarrhea experienced (Table iii) and is usually limited to loperamide. No antidiarrheal medication is taken prophylactically because constipation is a risk, especially if the patient is already taking narcotics for pain management, and because not all patients will develop diarrhea. Should diarrhea arise, the patient's current medication should be reviewed, with an emphasis on the removal of stool softeners and laxatives.
Before patients initiate egfr tki therapy, they should be prescribed an antidiarrheal agent such as loperamide and be advised to start taking it immediately upon onset of diarrhea. For mild (grade 1) diarrhea, the patient should take 4 mg (2 tablets) of loperamide immediately after symptoms begin and then 2 mg (1 tablet) after each loose stool to a maximum of 20 mg daily until 12 hours have passed with no episodes of diarrhea. If diarrhea persists or becomes moderate (grade 2), the patient should continue with loperamide (to a maximum of 20 mg daily, as for grade 1) and be assessed for dehydration and electrolyte imbalances. If the diarrhea reaches grade 3 or 4, the patient should be hospitalized. At that point, loperamide should be continued, and aggressive intravenous fluid replacement should be initiated. In addition, infection should be ruled out by stool culture, and if the patient is neutropenic, antibiotics should be given prophylactically 8, 21 . Although it might not be necessary for the oncologist to consult with a gastroenterologist on an outpatient basis to manage a patient's diarrhea, a gastroenterologist might be consulted once a patient is admitted to hospital, especially if an endoscopic evaluation is required.
Alternatives to loperamide are diphenoxylate-atropine and codeine, either of which can be used with loperamide. Patients should take 5 mg (2 tablets) of diphenoxylate-atropine 4 times daily (maximum of 20 mg daily) or 30 mg codeine every 4 hours 29 .
The dose of the egfr tki should be maintained in the presence of grade 1 diarrhea. At grade 2, if the patient does not respond to loperamide after 48 hours, the egfr tki should be temporarily discontinued until the diarrhea returns to grade 1, at which time the egfr tki should be resumed using these guidelines:
• Lower the afatinib dose by 10 mg at a time to a minimum dose of 20 mg.
• Lower the erlotinib dose by 50 mg at a time to a minimum dose of 50 mg (no sufficient data on efficacy are available in the literature).
• Resume gefitinib only at the original dose (the dose of gefitinib cannot be lowered and no data on its efficacy with a modified schedule are available) 8, 21 .
For grade 3 or 4 diarrhea, the egfr tki should be withheld until diarrhea reaches grade 1, after which the egfr tki should be resumed using the guidelines already stated. The egfr tki should be permanently discontinued if diarrhea does not reach grade 1 within 14 days despite best supportive care and withholding of the tki 7,20 .
Earlier algorithms have suggested the use of octreotide if dose reduction or discontinuation of the egfr tki was ineffective 8 , but in practice, the need for octreotide is extremely rare, and no direct clinical study supports the efficacy of octreotide in egfr tki-induced diarrhea.
SUMMARY
In nsclc, targeting the egfr signalling pathway has been shown to be an effective strategy for treatment, resulting in improved clinical outcomes. The clinical success of these treatments is associated with a number of aes, including diarrhea. The efficacy of egfr tkis is frequently correlated with the presence of diarrhea.
The key to managing diarrhea is to educate patients about this ae before treatment starts. Patients should be monitored weekly for the first 4 weeks of treatment, which is the period during which diarrhea 
